Cell Transplantation最新文献

Pediatric organ transplant recipients have a higher risk for wait list mortality due to the scarcity of size matched organs. Neonatal organ donation could potentially ameliorate the discrepancy but is currently not implemented in Sweden. This study aims to evaluate the potential of neonatal organ donation in central Sweden using a standardized protocol with organ specific criteria. Data on 2,061 neonates who deceased in central Sweden from 2006 to 2016 were collected; 308 neonates met criteria for possible donation. Medical records of all possible donors were reviewed, identifying 85 potential donors. Main cause of death was hypoxic ischemic encephalopathy 47% (n = 40). Median weight was 2,355 (IQR: 1,953) g, with 31% receiving inotropic support. Median creatinine of 72 (IQR: 67) µmol/l, urine production 3 (IQR: 2.2) ml/kg/h, ALT 0.51 (IQR: 1.5) µkat/l, and AST 1.7 (IQR: 3.1) µkat/l. Criteria for kidney donation was met in 39 potential neonatal, 29 for liver and 18 for heart, corresponding to a potential increase of 1.9, 1.4, and 0.9 donors PMP per year, respectively. In total, 16 neonates had a catastrophic neurological injury in combination with lack of brainstem reflexes, indicating plausibility of donation after brain death. Expanding organ donation into the neonatal period in Sweden could lead to an increase in organs available for transplant.

Stem cell therapy has emerged as a promising strategy for inherited retinal diseases (IRDs), yet its global research trajectory has not been systematically mapped. This study analyzes publication trends, leading contributors, and thematic evolution of IRD stem cell therapy research from 2000 to 2024. Publications were retrieved from the Web of Science Core Collection and analyzed with CiteSpace and VOSviewer. We identified 1060 articles with a steady rise in annual output. The United States and China were the most prolific countries; University College London and the University of Iowa were major institutions; and key outlets included Stem Cell Research & Therapy, Investigative Ophthalmology & Visual Science, and Cell Transplantation. Keyword and co-citation analyses reveal a clear trajectory: early emphasis on stem cell-derived retinal pigment epithelium transplantation for photoreceptor rescue, subsequent expansion to photoreceptor precursor and retinal organoid replacement, and recent movement toward early clinical translation. Persisting challenges include long-term graft survival, functional integration, and immune compatibility. Overall, this bibliometric roadmap clarifies how the field is transitioning from foundational studies to translational application and highlights priorities for interdisciplinary collaboration to accelerate clinical advancement.

This study aimed to investigate whether soluble B-cell maturation antigen (sBCMA) levels could be predictive biomarker for short-term and long-term therapeutic efficacy and survival outcomes following anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma (R/R MM). We enrolled 29 R/R MM patients who received anti-BCMA CAR-T cell therapy. In short-term observation, proportion of MM cells, expression of B-cell maturation antigen (BCMA) and sBCMA in bone marrow (BM) were evaluated, along with adverse events, correlation between sBCMA levels and short-term efficacy or survival outcomes were evaluated. In long-term observation, expressions of sBCMA were observed up to 24 months after therapy or until disease progression again in patients who achieved an objective response (ORR). Progression-free survival (PFS), overall survival (OS), correlation between sBCMA levels, and long-term outcomes were analyzed. In short-term observation, high expressions of sBCMA in BM were associated with poor efficacy of CAR-T cell therapy, while the proportion of MM cells in BM and BCMA expression in MM cells were not associated with poor efficacy of therapy. After 2 months of infusion, sBCMA levels decreased significantly, especially in patients who obtained ORR. In long-term follow-up, for patients who achieved ORR, the sBCMA levels significantly increased again when their disease progressed once more. Notably, R/R MM patients with extramedullary disease (EMD) demonstrated a higher likelihood of disease progression again. In patients achieved ORR, peaks of CAR-T cells correlated with proportion of MM cells, not with BCMA and sBCMA expression. Additionally, sBCMA levels were independent of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) severity. We suggest that sBCMA levels in BM might serve as a predictive biomarker for anti-BCMA CAR-T cell therapy efficacy prior to treatment and for disease progression during long-term monitoring. The trail register name is China Clinical Trial Register. URL are https://www.chictr.org.cn/bin/project/edit?pid=28999 and https://www.chictr.org.cn/bin/project/edit?pid=53962. Registration numbers are ChiCTR1800017051 and ChiCTR2000033925.

Mesenchymal stem cells (MSCs) are considered to be effective treatments for various diseases, and a wide variety of clinical studies have been performed worldwide. However, substantial obstacles remain before they can be approved and disseminated as treatments. A major bottleneck is the elucidation of their mechanisms of action, and the molecules that are essential for their efficacy have not been fully characterized. In this paper, I review the studies that attempted to identify the key mediators of MSCs that are involved in their effects on disease using in vivo models. More specifically, studies are discussed in which reductions in the efficacy of MSCs in animal models of disease were induced by the absence of key mediators. The target diseases were lung, joint, cerebral nerve, or cardiac diseases and graft-versus-host disease (GVHD). The following molecules were identified and are discussed herein: TSG-6, VEGF, KGF, HGF, claudin-4, ANXA1, MANF, PYCR1, integrin β1, PDGFRβ, type-II collagen, CD151, TIMP3, TGF-β1, BDNF, COX-2, Botch, IL-1β, CTRP3, CXCR4, miR-34c, FSTL1, IDO, iNOS, IFNγR1, PGES, Chi3l1, and IL-6. These are key mediators of the efficacy of MSCs in vivo.

This editorial introduces a special issue on cell-based therapies for disorders affecting locomotor function. The articles span a range of approaches, including methods to enhance immunological compatibility in induced pluripotent stem cell transplantation, as well as clinical and preclinical investigations using mesenchymal stem cells for the treatment of osteoarthritis. These studies address different therapeutic strategies and stages of development, reflecting ongoing efforts to translate basic research into safe and practical treatments for locomotor conditions.

Patients with hair-loss experience stress and a loss of confidence. Several factors contribute to hair loss, including aging, androgen hormone effects, genetics, and diseases. Normally, physicians treat hair loss using medications such as minoxidil and finasteride. However, these treatments are associated with side effects and some limitations. Currently, hair transplantation is the most efficient technique; however, it requires the use of numerous hair grafts. Stem cell and hair follicle cell (HFC) treatments have been developed for hair-loss treatment. Previously, stem cell and HFC therapies have been shown to promote hair development, prolong the anagen phase, and increase hair diameter and density. In addition, growth factors and extracellular vesicles (EVs) are important for prolonging the anagen phase, improving hair follicle health, and reducing dihydrotestosterone effects. Furthermore, gene therapy and tissue engineering have also been developed as treatments for hair loss. In this review, we discuss (i) the basic knowledge and molecular signaling relevant to hair regeneration and (ii) advanced technology medical treatments for hair loss (stem cells, HFCs, growth factor, EVs, gene therapy, and tissue engineers).

A descriptive qualitative study was conducted to explore risk perception, self-management challenges, and coping strategies among Chinese hematopoietic stem cell transplantation (HSCT) patients, using the Health Action Process Approach (HAPA) as the guiding framework. Purposive sampling, based on the principle of information power, was employed to recruit 20 HSCT patients from a hospital in south-central China between May and August 2024. The HAPA model informed the development of semi-structured interview questions, and the data were analyzed using a combination of thematic analysis and framework analysis. The findings indicate that both risk perception and self-efficacy play a critical role in motivating patient engagement in self-management. Main barriers to self-management included difficulties in symptom control, lifestyle modification, psychological adjustment, and healthcare-related financial burdens. Effective coping strategies reported by participants involved the use of digital tools, seeking professional medical advice, maintaining self-management journals, and drawing on family and social support networks. In clinical practice, healthcare professionals may capitalize on the heightened risk perception and self-efficacy during the peri-transplant period to promote the transition from risk perception to actionable self-management behaviors. In contrast, during the early post-discharge phase, when both risk perception and self-efficacy tend to decline, tailored support systems and resource allocation are helpful for maintaining the transition from risk perception to self-management action.

Posaconazole (POS) tablets were approved for prophylaxis of invasive fungal disease (IFD) in patients with hematological disorders undergoing haploidentical allogeneic stem cell transplantation (haplo-HSCT). There is limited research on drug-drug interactions (DDIs) between POS, cyclosporine A (CsA), and mycophenolate mofetil (MMF), as well as the impact of POS on acute graft versus host disease (aGVHD) in haplo-HSCT patients receiving POS for secondary antifungal prophylaxis (SAP). This study aims to investigate the DDI between POS, CsA, and MMF, as well as the incidence of aGVHD in haplo-HSCT patients with prior-IFD. This is a single-arm, open-label, prospective trial. Plasma concentrations of POS, mycophenolic acid (MPA), and CsA were monitored within 30 days post-transplantation. In addition, the incidences of aGVHD and IFD were observed. Forty-six patients with prior-IFD were enrolled. POS reached a steady state by week 2, with the mean through blood concentration (TBC) of 0.54 ± 0.07 μg/mL. MPA achieved target levels by week 3 without dose adjustment, with a mean TBC of 0.84 ± 0.08 mg/L. The CsA TBC levels required individualized dose modifications. The incidences of grade II-IV and grade III-IV aGVHD were 47.83% and 21.74%, respectively. The breakthrough rate of SAP was 4.35% at 100 days and 10.86% at 6 months. The conclusions indicate that POS tablets do not require dose adjustments for MMF; however, CsA dosing must be individualized. POS tablets appear to be effective and well-tolerated for SAP in haplo-HSCT (the Chinese Clinical Trial Registry: www.chictr.org.cn (ChiCTR2200059472)).

Tubal factor infertility remains a major cause of female reproductive dysfunction. Current therapeutic options, such as surgical repair or in vitro fertilization, only bypass but do not restore the dysfunctional uterine tube. Recent advances in tissue engineering and regenerative medicine (TERM) highlight biomaterials and organoid systems as promising tools to regenerate oviductal tissue and thus support natural conception. The manuscript comprehensively reviews 42 studies focused solely on TERM of the uterine tubes. Current status of uterine tube tissue engineering demonstrates that natural polymers, including collagen and decellularized extracellular matrix, provide biocompatible scaffolds capable of mimicking native extracellular environments. Synthetic polymers enable adjustment of mechanical properties and reproducibility, while hydrogels offer a biomimetic 3D microenvironment that supports epithelial differentiation, angiogenesis, and embryo development. Moreover, uterine tube-derived organoids, in which the polymeric component plays a crucial role, provide physiologically relevant in vitro models for studying pathology, drug testing, and translational applications. Recent advances in 3D bioprinting and magnetic bioprinting have enabled the development of artificial uterine tube models that better mimic native tissue architecture and cell organization. These findings underscore the translational potential of biomaterial-based strategies for uterine tube regeneration. Their integration into reproductive medicine may offer novel therapeutic avenues for restoring tubal function, improving fertility outcomes, and advancing patient-specific approaches in the management of female infertility.

Selective depletion of TCRαβ+ and CD45RA+ subsets of apheresed hematopoietic progenitor cells, HPC(A), enables haploidentical hematopoietic stem cell transplant (haplo-HSCT) by circumventing risks of graft-versus-host disease. Here, we analyze our institution's large series of ex vivo T-cell depletion processes to review procedure performance and explore factors that affect depletion efficiency and graft composition. Over 6 years, 91 haploidentical donors underwent peripheral blood CD34+ stem cell mobilization with granulocyte-colony stimulating factor, with 12 (13%) receiving additional pre-emptive plerixafor. HPC(A) was split into two fractions for TCRαβ and CD45RA depletion with the CliniMACS PLUS device. TCRαβ depletion resulted in a median 4.3 (interquartile range, 4.1-4.5) log reduction, with CD34 recovery at 98% (94%-103%) and TCRγδ+ cell recovery at 89% (74%-98%). CD45RA depletion resulted in a median 4.8 (4.3-5.2) log reduction, with CD3+/CD45RO+ cell recovery at 41% (34%-47%) and CD34 recovery at 58% (51%-68%). TCRαβ depletion efficiency was maintained even when total nucleated cell counts exceeded the maximal specified number, provided the target fraction was within capacity of the depletion kit. Platelet contamination did not affect depletion efficacy or CD34 recovery. Age increases the proportion of CD45RO+ memory cells and TCRαβ subset in HPC(A), while plerixafor increases the latter. Although statistically significant correlation exists between pre-depletion cell composition and depletion performance for some cell subsets, the post-depletion product still met pre-specified threshold without being affected to a clinically relevant extent, over a wide range of input cell numbers. Such robustness of the depletion systems is critical for successful performance of haplo-HSCT.